The international European Academy of Neurology survey on neurological symptoms in patients with COVID-19 infection
The international European Academy of Neurology survey on neurological symptoms in patients with COVID-19 infection
复制标题
DOI：
10.1111/ene.14407
复制
发表时间：
2020-07-23
影响因子：
5.1
通讯作者：
von Oertzen, T. J.
中科院分区：
文献类型：
--
作者：
Moro, E.;Priori, A.;von Oertzen, T. J.
背景与目的虽然COVID-19感染的主要临床特征是肺部，但一些相关的神经体征、症状和疾病正在出现。神经系统并发症的发生率和特点尚不清楚。为此，欧洲神经病学学会（EAN）新冠肺炎核心工作组启动了对新冠肺炎患者观察到的神经系统症状的调查。方法在EAN网站上进行17个问题的在线调查，并于2020年4月9日开始分发给EAN会员和全球其他医生。结果截至2020年4月27日，从2343名应答者（4199人）中收集了适当的数据，其中82.0%是神经科医生，主要来自欧洲。大多数应答者（74.7%）主要在急诊室和COVID-19病房咨询COVID-19患者。大多数（67.0%）评估的COVID-19患者有神经系统表现（neuro COVID-19），少于10例。最常见的神经学表现为头痛（61.9%）、肌痛（50.4%）、嗅觉缺失（49.2%）、老年痴呆（39.8%）、意识受损（29.3%）和精神运动性躁动（26.7%）。脑病和急性脑血管疾病占21.0%。神经系统表现通常被解释为可能与COVID-19有关；它们最常见于有多种一般症状的患者，并发生在感染期间的任何时间。结论神经科医生目前积极参与与COVID-19大流行相关的神经系统问题的管理。这项调查证明建立前瞻性登记是合理的，以便更好地了解神经系统COVID-19患者的患病率、神经系统疾病特征以及神经系统表现对结果的贡献。
Background and purpose Although the main clinical features of COVID-19 infection are pulmonary, several associated neurological signs, symptoms and diseases are emerging. The incidence and characteristics of neurological complications are unclear. For this reason, the European Academy of Neurology (EAN) core COVID-19 Task Force initiated a survey on neurological symptoms observed in patients with COVID-19 infection. Methods A 17-question online survey was made available on the EAN website and distributed to EAN members and other worldwide physicians starting on 9 April 2020. Results By 27 April 2020, proper data were collected from 2343 responders (out of 4199), of whom 82.0% were neurologists, mostly from Europe. Most responders (74.7%) consulted patients with COVID-19 mainly in emergency rooms and in COVID-19 units. The majority (67.0%) had evaluated fewer than 10 patients with neurological manifestations of COVID-19 (neuro COVID-19). The most frequently reported neurological findings were headache (61.9%), myalgia (50.4%), anosmia (49.2%), ageusia (39.8%), impaired consciousness (29.3%) and psychomotor agitation (26.7%). Encephalopathy and acute cerebrovascular disorders were reported at 21.0%. Neurological manifestations were generally interpreted as being possibly related to COVID-19; they were most commonly recognized in patients with multiple general symptoms and occurred at any time during infection. Conclusion Neurologists are currently and actively involved in the management of neurological issues related to the COVID-19 pandemic. This survey justifies setting up a prospective registry to better capture the prevalence of patients with neuro COVID-19, neurological disease characteristics and the contribution of neurological manifestations to outcome.